- Harrow recently highlighted three new clinical and real-world studies for its retina portfolio at the 2026 ASRS Annual Meeting, including interim randomized data and a nearly 20,000‑injection safety analysis for IHEEZO, plus interim post‑marketing findings for BYOOVIZ from Samsung Bioepis.
- The early signals of improved post‑injection patient experience with IHEEZO, alongside large‑scale safety data and expanding evidence for BYOOVIZ, strengthen the clinical underpinnings of Harrow’s retina franchise.
- We’ll now examine how IHEEZO’s early pain‑reduction signal and broader evidence base could influence Harrow’s existing investment narrative.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Harrow Investment Narrative Recap
To own Harrow, you need to believe its focused ophthalmic portfolio can convert clinical adoption of products like IHEEZO and BYOOVIZ into improving revenue and, over time, earnings, despite current losses and premium pricing. The key near term catalyst remains execution against 2026 revenue guidance and delivery of pivotal data like the QUELL trial, while the largest risk is that core launches underperform expectations. The new ASRS data supports IHEEZO’s profile but does not, on its own, materially change that balance.
Among recent announcements, the FDA cleared IND for Harrow’s Phase 3 TRIESENCE trial in cataract surgery pain and inflammation stands out alongside the ASRS retina data. Together, they frame Harrow’s near term catalysts as both commercial uptake of current retina assets and clinical milestones for pipeline products such as TRIESENCE. If either path stumbles, the company’s reliance on a handful of flagship brands could become more of a constraint than a strength.
Yet behind these encouraging retina signals, the risk that Harrow’s launch dependent model struggles if pricing or uptake disappoints is something investors should be aware of...
Read the full narrative on Harrow (it's free!)
Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029.
Uncover how Harrow's forecasts yield a $68.38 fair value, a 54% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming Harrow must reach about US$707,000,000 in revenue and US$140,000,000 in earnings by 2029, so this new IHEEZO and BYOOVIZ evidence could either ease or heighten their concern that launch and reimbursement risks remain underappreciated.
Explore 3 other fair value estimates on Harrow - why the stock might be worth over 7x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.
No Opportunity In Harrow?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com